Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867307 · ClinicalTrials.gov registry record · Phase 2
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
A Phase 2 study of Healthy and Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01867307 is a Phase 2 study of Healthy and Diabetes Mellitus, Type 2 that has completed, run by Boehringer Ingelheim. The registered enrollment target is 39 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01867307, a Phase 2 study of Healthy and Diabetes Mellitus, Type 2, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
Conditions Studied
Interventions
- DRUG Empagliflozin
- DRUG BI 10773
Study Locations (1)
Texas
- Boehringer Ingelheim Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867307
The ClinicalTrials.gov registry entry for NCT01867307 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin is the first listed.
NCT01867307 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01867307 about?
NCT01867307 is a clinical study titled "Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls". Single center, 14-day, open-label trial to examine the effect of 25 mg q.d. empagliflozin on kinetics of renal glucose reabsorption in patients diagnosed with type 2 diabetes mellitus and healthy controls
What is the current status of trial NCT01867307?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2013-06. Estimated completion is 2015-10.
What conditions does trial NCT01867307 study?
This clinical trial studies the following conditions: Healthy, Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01867307?
The interventions under investigation include: Empagliflozin (DRUG), BI 10773 (DRUG).
Who is sponsoring clinical trial NCT01867307?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01867307 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.